Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
AI-Powered Drug Development Pipeline Highlights: LP-300 Lantern’s Phase 2 HARMONIC™ trial for LP-300 continued to advance during Q1 2025 with…
Xero CEO on FY Results, Business Strategy
Sukhinder Singh Cassidy, CEO at Xero, discusses the company’s full-year results and outlook for its business strategy. She speaks with…